Tuesday, August 16, 2022
HomeHealth & FitnessWHO approves use of new HIV prevention injectable drug

WHO approves use of new HIV prevention injectable drug

The World Health Organization has approved the use of a monthly injectable drug as an additional preventive measure against contracting HIV.

The long-acting injection is a form of pre-exposure prophylaxis, also known as PrEP. It works by preventing HIV from replicating in one’s body.

The first two injections will be administered four weeks apart, followed thereafter by an injection every eight weeks.

“Long-acting cabotegravir is a safe and highly effective HIV prevention tool, but isn’t yet available outside study settings,” Dr Meg Doherty said in a statement.

He added: “We hope these new guidelines will help accelerate country efforts to start to plan and deliver CAB-LA alongside other HIV prevention options, including oral PrEP and the dapivirine vaginal ring.”

LEAVE A REPLY

Please enter your comment!
Please enter your name here